A Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer With Gradual or Potential Progression After EGFR-TKIs Treatment

Clinical trial NCT07669051 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT07669051
Sponsor: Shandong Cancer Hospital and Institute
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

NSCLC (Advanced Non-small Cell Lung Cancer)

Start date: 2026-01-01
Primary completion: 2028-01-01
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.